Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stomach Neoplasms | 14 | 2020 | 266 | 3.760 |
Why?
|
| Neuroendocrine Tumors | 7 | 2023 | 105 | 2.810 |
Why?
|
| Adenocarcinoma | 14 | 2022 | 1169 | 2.120 |
Why?
|
| Gastritis | 3 | 2023 | 32 | 1.920 |
Why?
|
| Pancreatic Neoplasms | 5 | 2022 | 645 | 1.570 |
Why?
|
| Biomarkers, Tumor | 9 | 2019 | 1464 | 1.420 |
Why?
|
| Immunohistochemistry | 9 | 2021 | 1753 | 1.110 |
Why?
|
| Gastric Mucosa | 4 | 2019 | 66 | 1.060 |
Why?
|
| Gastritis, Atrophic | 1 | 2023 | 3 | 0.960 |
Why?
|
| Adenoma | 3 | 2019 | 235 | 0.910 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 526 | 0.790 |
Why?
|
| Helicobacter Infections | 1 | 2021 | 34 | 0.780 |
Why?
|
| Barrett Esophagus | 2 | 2021 | 93 | 0.780 |
Why?
|
| Helicobacter pylori | 1 | 2021 | 35 | 0.780 |
Why?
|
| Plasma Cells | 1 | 2021 | 80 | 0.770 |
Why?
|
| Stomach | 1 | 2021 | 108 | 0.760 |
Why?
|
| Microsatellite Instability | 2 | 2019 | 43 | 0.730 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 938 | 0.700 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2022 | 549 | 0.690 |
Why?
|
| Colitis, Lymphocytic | 1 | 2018 | 3 | 0.650 |
Why?
|
| Antidiarrheals | 1 | 2018 | 14 | 0.640 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 223 | 0.640 |
Why?
|
| Metaplasia | 1 | 2018 | 37 | 0.640 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2017 | 3 | 0.640 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2017 | 11 | 0.630 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 456 | 0.630 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 250 | 0.620 |
Why?
|
| Mesalamine | 1 | 2018 | 88 | 0.600 |
Why?
|
| Carcinogenesis | 1 | 2019 | 195 | 0.600 |
Why?
|
| Steroids | 1 | 2018 | 177 | 0.580 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 394 | 0.570 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 2271 | 0.560 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 18 | 0.540 |
Why?
|
| Humans | 48 | 2023 | 86643 | 0.530 |
Why?
|
| Aged | 20 | 2022 | 18415 | 0.510 |
Why?
|
| Biopsy | 5 | 2023 | 1163 | 0.500 |
Why?
|
| Female | 31 | 2022 | 44532 | 0.480 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 6509 | 0.470 |
Why?
|
| Middle Aged | 22 | 2022 | 25028 | 0.470 |
Why?
|
| Adult | 22 | 2022 | 25648 | 0.430 |
Why?
|
| Male | 29 | 2022 | 40965 | 0.430 |
Why?
|
| Intermediate Filament Proteins | 1 | 2012 | 35 | 0.430 |
Why?
|
| Nevus | 1 | 2012 | 15 | 0.430 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1673 | 0.430 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 381 | 0.410 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 141 | 0.410 |
Why?
|
| Mutation | 2 | 2019 | 3968 | 0.400 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2022 | 21 | 0.400 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 196 | 0.380 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 143 | 0.380 |
Why?
|
| Goblet Cells | 2 | 2022 | 19 | 0.380 |
Why?
|
| Leukemia, Lymphoid | 1 | 2010 | 72 | 0.370 |
Why?
|
| Skin Neoplasms | 2 | 2012 | 546 | 0.370 |
Why?
|
| Inclusion Bodies | 1 | 2010 | 34 | 0.370 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 2262 | 0.370 |
Why?
|
| Mastocytosis, Systemic | 1 | 2009 | 11 | 0.350 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 503 | 0.340 |
Why?
|
| Breast Diseases | 1 | 2009 | 97 | 0.330 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 321 | 0.320 |
Why?
|
| Lymphocytes | 1 | 2010 | 464 | 0.320 |
Why?
|
| Melanoma | 1 | 2012 | 459 | 0.310 |
Why?
|
| Adolescent | 10 | 2021 | 8981 | 0.310 |
Why?
|
| Herpesvirus 4, Human | 2 | 2019 | 114 | 0.300 |
Why?
|
| Young Adult | 9 | 2021 | 5976 | 0.300 |
Why?
|
| Cysticercosis | 1 | 2007 | 2 | 0.300 |
Why?
|
| Cadherins | 2 | 2019 | 151 | 0.300 |
Why?
|
| Submandibular Gland Diseases | 1 | 2007 | 9 | 0.300 |
Why?
|
| Lip Neoplasms | 1 | 2006 | 8 | 0.290 |
Why?
|
| Salivary Glands, Minor | 1 | 2006 | 9 | 0.290 |
Why?
|
| Carcinoma | 2 | 2019 | 436 | 0.280 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2006 | 66 | 0.270 |
Why?
|
| Intestinal Mucosa | 2 | 2022 | 797 | 0.250 |
Why?
|
| Exodeoxyribonucleases | 1 | 2023 | 14 | 0.240 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 930 | 0.240 |
Why?
|
| Biology | 1 | 2023 | 50 | 0.230 |
Why?
|
| Opportunistic Infections | 2 | 2022 | 59 | 0.230 |
Why?
|
| Lymphocytosis | 1 | 2022 | 10 | 0.220 |
Why?
|
| Enterocolitis | 1 | 2022 | 12 | 0.220 |
Why?
|
| Mitotic Index | 1 | 2022 | 20 | 0.210 |
Why?
|
| Aberrant Crypt Foci | 1 | 2022 | 7 | 0.210 |
Why?
|
| Tissue Array Analysis | 2 | 2019 | 124 | 0.210 |
Why?
|
| Reference Standards | 1 | 2022 | 159 | 0.210 |
Why?
|
| Cytomegalovirus Infections | 1 | 2022 | 144 | 0.200 |
Why?
|
| Gastroscopy | 1 | 2021 | 23 | 0.200 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 357 | 0.200 |
Why?
|
| Catheter Ablation | 1 | 2023 | 233 | 0.200 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 112 | 0.190 |
Why?
|
| Pathologists | 1 | 2021 | 24 | 0.190 |
Why?
|
| Gastrointestinal Tract | 2 | 2021 | 191 | 0.190 |
Why?
|
| Interferon Regulatory Factors | 1 | 2021 | 67 | 0.190 |
Why?
|
| Collagen | 2 | 2022 | 269 | 0.190 |
Why?
|
| Lifting | 1 | 2020 | 12 | 0.190 |
Why?
|
| Duodenal Neoplasms | 1 | 2019 | 19 | 0.180 |
Why?
|
| Republic of Korea | 1 | 2019 | 31 | 0.180 |
Why?
|
| Biomarkers | 2 | 2021 | 1718 | 0.180 |
Why?
|
| Smad4 Protein | 1 | 2019 | 23 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 1076 | 0.180 |
Why?
|
| Actinomycosis | 1 | 2019 | 12 | 0.180 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2019 | 10 | 0.180 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 40 | 0.170 |
Why?
|
| Disease Progression | 3 | 2018 | 1531 | 0.170 |
Why?
|
| Observer Variation | 1 | 2021 | 602 | 0.170 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 17 | 0.170 |
Why?
|
| In Situ Hybridization | 2 | 2017 | 307 | 0.170 |
Why?
|
| Retrospective Studies | 7 | 2023 | 8489 | 0.170 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 51 | 0.170 |
Why?
|
| Appendicitis | 1 | 2019 | 62 | 0.170 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 184 | 0.170 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 79 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 645 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 185 | 0.160 |
Why?
|
| Bismuth | 1 | 2018 | 8 | 0.160 |
Why?
|
| Carcinoid Tumor | 1 | 2018 | 42 | 0.160 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 154 | 0.160 |
Why?
|
| Child, Preschool | 3 | 2021 | 3612 | 0.160 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2705 | 0.160 |
Why?
|
| Appendiceal Neoplasms | 1 | 2018 | 27 | 0.160 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2018 | 23 | 0.160 |
Why?
|
| Salicylates | 1 | 2018 | 25 | 0.160 |
Why?
|
| Acinar Cells | 1 | 2017 | 6 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2019 | 458 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 479 | 0.160 |
Why?
|
| Gene Amplification | 1 | 2018 | 131 | 0.150 |
Why?
|
| Lung | 2 | 2022 | 1170 | 0.150 |
Why?
|
| Cetuximab | 1 | 2018 | 113 | 0.150 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 1565 | 0.150 |
Why?
|
| Endoscopy, Digestive System | 1 | 2017 | 65 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 736 | 0.150 |
Why?
|
| Microscopy, Electron | 1 | 2017 | 503 | 0.150 |
Why?
|
| Camptothecin | 1 | 2018 | 189 | 0.150 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 132 | 0.150 |
Why?
|
| Flow Cytometry | 1 | 2019 | 679 | 0.150 |
Why?
|
| Cecum | 1 | 2016 | 68 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2018 | 217 | 0.150 |
Why?
|
| Anemia | 1 | 2017 | 128 | 0.140 |
Why?
|
| Phenotype | 2 | 2019 | 2378 | 0.140 |
Why?
|
| Child | 4 | 2021 | 6927 | 0.140 |
Why?
|
| Stomach Diseases | 1 | 2015 | 19 | 0.140 |
Why?
|
| Polyps | 1 | 2015 | 28 | 0.130 |
Why?
|
| Colitis, Ulcerative | 1 | 2022 | 711 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 329 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2017 | 695 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2023 | 7993 | 0.130 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 556 | 0.120 |
Why?
|
| Population | 1 | 2013 | 35 | 0.120 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 44 | 0.110 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2013 | 12 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2017 | 395 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2013 | 70 | 0.110 |
Why?
|
| Nestin | 1 | 2012 | 18 | 0.110 |
Why?
|
| Genomics | 1 | 2017 | 720 | 0.100 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2011 | 2 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 157 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2019 | 2767 | 0.100 |
Why?
|
| Microbiota | 1 | 2016 | 381 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2438 | 0.100 |
Why?
|
| Age Factors | 1 | 2016 | 1851 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 318 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 552 | 0.090 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2010 | 4 | 0.090 |
Why?
|
| United States | 2 | 2019 | 6672 | 0.090 |
Why?
|
| Mast Cells | 1 | 2009 | 92 | 0.080 |
Why?
|
| Leucovorin | 2 | 2020 | 218 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2009 | 81 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2010 | 435 | 0.080 |
Why?
|
| Fever | 1 | 2008 | 125 | 0.080 |
Why?
|
| Wuchereria bancrofti | 1 | 2007 | 2 | 0.080 |
Why?
|
| Filariasis | 1 | 2007 | 5 | 0.080 |
Why?
|
| Lung Abscess | 1 | 2007 | 5 | 0.080 |
Why?
|
| Histiocytosis, Sinus | 1 | 2007 | 14 | 0.080 |
Why?
|
| Lymphatic Diseases | 1 | 2007 | 37 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 2903 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 266 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2020 | 556 | 0.070 |
Why?
|
| Mammaplasty | 1 | 2009 | 107 | 0.070 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2007 | 7 | 0.070 |
Why?
|
| Keratins | 1 | 2006 | 63 | 0.070 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2007 | 58 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2010 | 971 | 0.070 |
Why?
|
| Granuloma | 2 | 2019 | 65 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2357 | 0.060 |
Why?
|
| Prognosis | 1 | 2012 | 3679 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 2426 | 0.060 |
Why?
|
| Microwaves | 1 | 2023 | 34 | 0.060 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 10 | 0.060 |
Why?
|
| Ulcer | 1 | 2022 | 36 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2023 | 166 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 76 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 46 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 117 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2022 | 84 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 80 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2022 | 85 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2022 | 148 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 72 | 0.050 |
Why?
|
| India | 2 | 2013 | 120 | 0.050 |
Why?
|
| Chondroitin Sulfates | 1 | 2021 | 43 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 231 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 171 | 0.050 |
Why?
|
| Hydrogels | 1 | 2021 | 82 | 0.050 |
Why?
|
| Injections | 1 | 2020 | 109 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 927 | 0.050 |
Why?
|
| Mentors | 1 | 2021 | 76 | 0.050 |
Why?
|
| DNA Repair | 1 | 2022 | 356 | 0.040 |
Why?
|
| Actinomyces | 1 | 2019 | 5 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 178 | 0.040 |
Why?
|
| Intestinal Polyps | 1 | 2019 | 26 | 0.040 |
Why?
|
| Duodenum | 1 | 2019 | 100 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 106 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 72 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 56 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 329 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 94 | 0.040 |
Why?
|
| Endoscopy | 1 | 2020 | 332 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2007 | 93 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 55 | 0.040 |
Why?
|
| Chicago | 1 | 2020 | 1379 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 115 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 427 | 0.030 |
Why?
|
| Mice | 2 | 2021 | 11352 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1204 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1851 | 0.030 |
Why?
|
| Endosonography | 1 | 2015 | 96 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 485 | 0.030 |
Why?
|
| Homeostasis | 1 | 2016 | 409 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 853 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 217 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C8 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 486 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2013 | 147 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 1939 | 0.030 |
Why?
|
| Axilla | 1 | 2013 | 99 | 0.030 |
Why?
|
| Animals | 3 | 2021 | 26582 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2013 | 93 | 0.030 |
Why?
|
| Schwann Cells | 1 | 2011 | 34 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1313 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2013 | 677 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1577 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1981 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2011 | 143 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 160 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3092 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2010 | 130 | 0.020 |
Why?
|
| Microscopy | 1 | 2010 | 87 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2010 | 115 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 4213 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2013 | 533 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1686 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2008 | 14 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2008 | 48 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 1056 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2360 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1920 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 235 | 0.020 |
Why?
|
| Chin | 1 | 2007 | 8 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2011 | 669 | 0.020 |
Why?
|